Akebia Therapeutics | AKBA - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amgen USD 1.58B 354M 2026-03
Ardelyx USD 75.92M 7.69M 2025-12
Astellas Pharma JPY 234.7B 12.92B 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Bayer EUR 3.7B 356M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Celltrion KRW 12.71B 237.27B 2025-12
Cspc Pharmaceutical CNY 1.87B 95.62M 2025-12
Deva Holding AS TRY 462.26M 48.18M 2023-09
Dianthus Therapeutics USD 6.57M 1.62M 2025-12
Exelixis USD 139.6M 16.58M 2026-03
Fresenius Medical Care EUR 749M 36M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
J&J USD 6.03B 719M 2026-03
Kangmei Pharma CNY 237.06M 37.35M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Knight Therapeutics CAD 35.45M 4.43M 2025-12
Laboratorios Farma EUR 35.32M 2.75M 2025-06
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
Malin Corporation EUR 1.1M 400K 2024-12
Medical Developments International AUD 2.84M 4.19M 2025-12
Moderna USD 173M 135M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neuren Pharmaceuticals AUD 3.74M 2.5M 2025-12
Organigram Holdings CAD 7.73M 1.13M 2025-12
Ovoca Bio EUR 632K 2.33M 2025-06
Pharma Mar EUR 15.31M 2M 2026-03
Prothena USD 7.65M 5.59M 2025-12
PTC Therapeutics USD 73.89M 13.31M 2026-03
Qiagen NV USD 153.88M 10.77M 2025-12
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.33B 419M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Sartorius EUR 221.3M 500K 2026-03
Sino Biopharmaceutical CNY 7.54B 2.23B 2025-06
Tectonic Therapeutic USD 3.44M 1.52M 2025-12
Tilray USD 24.85M 1.7M 2025-09
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Zealand Pharma A/S 91.81M 99.04M 2025-12
Zz Pientze Pharmaceu CNY 214.31M 42.4M 2026-03